Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 8/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25586411 | 0.82 | GRM5 (0.40) | MAP3K14GRM5PDE3BPDE3ARIPK1 | |
| SCHEMBL30387134 | 0.81 | RIPK1 (0.47) | GRM5RIPK1 | |
| SCHEMBL25584836 | 0.81 | RIPK1 (0.47) | GRM5RIPK1 | |
| SCHEMBL24076698 | 0.80 | TDP1 (0.44) | TDP1PSMD14RXFP1GPR84RIPK1 | |
| SCHEMBL23075920 | 0.79 | RIPK1 (0.48) | MAP3K14GRM5PDE3BPDE3ARIPK1 | |
| SCHEMBL25584896 | 0.77 | GRM5 (0.35) | MAP3K14GRM5RIPK1 | |
| SCHEMBL25584909 | 0.76 | MAP3K14 (0.38) | MAP3K14GRM5PDE3BPDE3ARIPK1 | |
| SCHEMBL23081626 | 0.76 | MAP3K14 (0.46) | MAP3K14RIPK1 | |
| SCHEMBL23085749 | 0.76 | MAP3K14 (0.37) | MAP3K14GRM5PDE3BPDE3A | |
| SCHEMBL23085558 | 0.76 | GABRA1 (0.41) | MAP3K14GRM5PDE3BPDE3ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | TDP1 1005/4885PSMD14 1598/4885RXFP1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.